A week 68 check-in from the Sweatpants & Champagne channel. Her loss is slower now, though she says her body keeps changing.
Recap by typeshit. Full story at Sweatpants & Champagne.
TIKR points to retatrutide, due for filing in early 2027, and says a pending Seventh Circuit ruling on whether it counts as a biologic could decide 5 vs 12 years of exclusivity.
She lost 7 kilos in her first month, regained it during a month-long break, and now says she's eating more and gaining in week two back.
A shared report on doctors turning to GLP-1 medications for weight loss in some kids. Details are thin, so tap through for the full story.
The author, who holds Novo shares, cites Morgan Stanley's $190 billion obesity market forecast for 2035 and an NIH-funded mouse study on aging.
In Touch Weekly reports the March 2025 death was caused by anaphylaxis and was Australia's first death of its kind linked to anti-aging drugs.
8:11
A peptide-focused creator runs through retatrutide side effects aimed at men. Her claims aren't backed by sources given, so treat them as her take.
Loading…